Erzotabart
Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity[1].
Product Specifications
CAS Number
[2430792-01-9]
Product Name Alternative
GEN3014
UNSPSC
12352203
Target
CD38
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/erzotabart.html
Purity
99.00
Solubility
H2O
Smiles
[Erzotabart]
Molecular Weight
(145.056 kDa)
References & Citations
[1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 36, No. 4, 2022.|[2]Grosicki S, et al. GEN3014 (HexaBody®-CD38) in anti-CD38 Mab-naive patients with relapsed/refractory multiple myeloma: preliminary results from a dose-expansion cohort of a phase 1/2 trial[J]. Blood, 2023, 142: 4757.|[3]Hiemstra IH, et al., Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity. EBioMedicine. 2023 Jul;93:104663.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
